Fujian Shengdi Pharmaceutical Co., Ltd.

This study tests if a new medicine, HRS9531, can lower the chance of major heart problems like heart attacks and strokes in people with hardened arteries. About 9,262 adults with heart disease will receive either the drug or a placebo. The goal is to see if the drug helps control…

This early-stage trial tests a new injection called HRS9531 in Chinese adolescents aged 12 to 17 who have obesity. The study compares the drug to a placebo to check its safety and how the body processes it. About 48 participants will join, and they must have been on a stable diet…

This early-stage study looks at how the body processes HRS9531, a drug for diabetes and weight loss, in people with mild or moderate liver issues compared to those with healthy livers. About 24 adults will receive a single dose to measure drug levels and check for side effects. T…